# Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

> **NCT06767813** · PHASE2 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** TQB2868 injection
- **DRUG:** Gemcitabine injection
- **DRUG:** Albumin paclitaxel injection
- **DRUG:** Anlotinib capsules

## Key facts

- **NCT ID:** NCT06767813
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-19
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06767813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06767813, "Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06767813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*